Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 238-677-1 | CAS number: 14634-93-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: scientifically acceptable and sufficient documented
- Objective of study:
- metabolism
- Principles of method if other than guideline:
- After oral administration of 1000 mg/kg of ZEPC to Wistar rats female rats, the metabolites in the blood were extracted with ethyl acetate.
- GLP compliance:
- no
- Specific details on test material used for the study:
- No data.
- Radiolabelling:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- No data
- Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Details on exposure:
- No data
- Duration and frequency of treatment / exposure:
- No data
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose / concentration:
- No data
- Control animals:
- not specified
- Positive control reference chemical:
- No data
- Details on study design:
- Metabolites in the blood were extracted with ethyl acetate and identified by GC-MS.
- Type:
- metabolism
- Results:
- N-ethylaniline and Aniline were identified as metabolites
- Details on absorption:
- No data
- Details on distribution in tissues:
- No data
- Details on excretion:
- No data
- Metabolites identified:
- yes
- Details on metabolites:
- N-ethylaniline and Aniline were identified as metabolites.
- Conclusions:
- N-ethylaniline and Aniline were idetified as metabolites.
- Executive summary:
After oral adminisatration of 1000 mg/kg of ZEPC to Wistar rats female rats, the metabolites in the blood were extracted with ethyl acetate. N-ethylaniline (N-EA) and Aniline (AN) were identified as metabolites. N-EA and AN concentrations in the blood reached maximum levels (10.0 and 2.01 µg/ml) after 24 hr and then decreased to less than 0.3 µg/ml within 3 days. The increased methemoglobin levels in the blood after administration of ZEPC were nearly proportional to the changes in blood concentrations.
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: scientifically acceptable and sufficient documented
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- To 4 groups of rats, 5-6 weeks old, a mixture of radioactive labelled zinc ethylphenyldithiocarbamate was administered orally by gavage. After 3, 6, 24 and 72 hours blood, faeces, urine as well as liver, lungs, spleen, kidneys and fatty tissue were examined for radioactivity.
- GLP compliance:
- no
- Specific details on test material used for the study:
- 14C labelled zinc ethylphenyldithiocarbamate was used.
- Radiolabelling:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- not specified
- Route of administration:
- oral: gavage
- Vehicle:
- methylcellulose
- Duration and frequency of treatment / exposure:
- single application
- Dose / conc.:
- 688.5 mg/kg bw (total dose)
- Remarks:
- 266.5 mg ladiolabbeled (14C) and 422 mg unlabelled inc ethylphenylditiocarbamate/kg bw
- No. of animals per sex per dose / concentration:
- 4 groups of 5 rats each/dose
- Control animals:
- not specified
- Positive control reference chemical:
- None
- Details on dosing and sampling:
- After 3, 6, 24 and 72 hours bllod, faeces, urin aswell as liver, lungs, spleen, kidneys and fatty tissue were examined for radioactivity.
- Type:
- absorption
- Results:
- As 25% of radioactivity was excreted via urine, it was also inferred that 25-40% of administered zinc ethylphenyldithiocarbamate was absorbed via gastro intestinal tract.
- Details on absorption:
- The percentage of excretion into faeces was about 60% in 24 hr and about 65% in 72 hr, while that into urine was about 15% in 24 hr and about 25% in 72 hr. As 25% of radioactivity was excreted via urine, it was also inferred that 25-40% of administered zinc ethylphenyldithiocarbamate was absorbed via gastro intestinal tract.
- Details on distribution in tissues:
- All organs and tissues examined showed the highest radioactivity 3 - 6 hours after the oral administration and the radioactivity declined with time. In the early stage after the administration, the radioactivity was highest in the blood, followed by the liver and kidney. Although the radioactivity decreased with time, the liver and kidney still showed higher levels after 24 hr than other organs and tissues.
- Test no.:
- #1
- Transfer type:
- other:
- Observation:
- other: All organs and tissues examined showed the highest radioactivity 3 - 6 hours after the oral administration and the radioactivity declined with time.
- Test no.:
- #1
- Toxicokinetic parameters:
- other: At the beginning, the radioactivity was highest in the blood, followed by the liver and kidney. Although the radioactivity decreased with time, the liver and kidney still showed higher levels after 24 hr than other organs and tissues.
- Metabolites identified:
- yes
- Details on metabolites:
- In the urine N-ethylaniline, aniline and p-acetoaminophenol were found as metabolites.
- Conclusions:
- About 25-40% of administered zinc ethylphenyldithiocarbamate was absorbed via gastro intestinal tract. In the early stage after the administration, the radioactivity was highest in the blood, followed by the liver and kidney. Although the radioactivity decreased with time, the liver and kidney still showed higher levels after 24 hr than other organs and tissues. In the urine N-ethylaniline, aniline and p-acetoaminophenol were found as metabolites.
- Executive summary:
To 4 groups of rats, 5-6 weeks old, a mixture of radioactive labelled zinc ethylphenyldithiocarbamate was administered orally by gavage. After 3, 6, 24 and 72 hours blood, faeces, urine as well as liver, lungs, spleen, kidneys and fatty tissue were examined for radioactivity.
The percentage of excretion into faeces was about 60% in 24 hr and about 65% in 72 hr, while that into urine was about 15% in 24 hr and about 25% in 72 hr. As 25% of radioactivity was excreted via urine, it was also inferred that 25-40% of administered zinc ethylphenyldithiocarbamate was absorbed via gastro intestinal tract. All organs and tissues examined showed the highest radioactivity 3 - 6 hours after the oral administration and the radioactivity declined with time. In the early stage after the administration, the radioactivity was highest in the blood, followed by the liver and kidney. Although the radioactivity decreased with time, the liver and kidney still showed higher levels after 24 hr than other organs and tissues. In the urine N-ethylaniline, aniline and p-acetoaminophenol were found as metabolites.
Referenceopen allclose all
Description of key information
In a toxicokinetik study to 4 groups of rats, 5-6 weeks old, a mixture of radioactive labelled zinc ethylphenyldithiocarbamate was administered orally by gavage. After 3, 6, 24 and 72 hours blood, faeces, urine as well as liver, lungs, spleen, kidneys and fatty tissue were examined for radioactivity. The percentage of excretion into faeces was about 60% in 24 hr and about 65% in 72 hr, while that into urine was about 15% in 24 hr and about 25% in 72 hr. As 25% of radioactivity was excreted via urine, it was also inferred that 25-40% of administered zinc ethylphenyldithiocarbamate was absorbed via gastro intestinal tract. All organs and tissues examined showed the highest radioactivity 3 - 6 hours after the oral administration and the radioactivity declined with time. In the early stage after the administration, the radioactivity was highest in the blood, followed by the liver and kidney. Although the radioactivity decreased with time, the liver and kidney still showed higher levels after 24 hr than other organs and tissues. In the urine N-ethylaniline, aniline and p-acetoaminophenol were found as metabolites.
In another study, after oral administration of 1000 mg/kg of ZEPC to Wistar rats female rats, the metabolites in the blood were extracted with ethyl acetate. N-ethylaniline (N-EA) and aniline (AN) were identified as metabolites. N-EA and AN concentrations in the blood reached maximum levels (10.0 and 2.01 µg/ml) after 24 hr and then decreased to less than 0.3 µg/ml within 3 days. The increased methemoglobin levels in the blood after administration of ZEPC were nearly proportional to the changes in blood concentrations.
For zinc ethylphenyldithiocarbamate a reaction to the carcinogenic ethylphenylnitrosamine can be expected with nitrosating agents. Technical products can be contaminated with the respective nitrosamines (Toxicological evaluations of the BG Chemie for zinc ethylphenyldithiocarbamate No. 219 in German).
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.